Background: Interleukin (IL)-17A is proinflammatory cytokine produced by Th17 cells, which play key, but sometimes inconsistent role in autoimmunity and cancer. Polymorphic variants in IL-17A gene were differentially associated with susceptibility to cancer, including colorectal cancer (CRC). Aim: We investigated the association between six IL-17A gene variants (rs3819024, rs2275913, rs3819025, rs10484879, rs7747909, and rs3748067) with CRC susceptibility in Tunisians. Subjects and Methods: Retrospective case-control study. Study subjects comprised 293 patients with CRC, and 268 age-, gender-, and BMI-matched healthy controls. IL-17A genotyping was done by real-time PCR, with defined clusters.
Introduction
Colorectal cancer (CRC) is a malignant tumor of the large intestine with rising frequency worldwide, and a major global public health concern [1, 2] . With approximately 608,000 deaths attributed to it worldwide, CRC accounts for 8% of all cancer deaths, and is numerically the fourth common cause of cancer deaths [2] . The prevalence of CRC is estimated at 6.3/100,000 per year in Tunisia [3] , with comparable incidence in males and females. The diagnosis CRC is made on clinical (abdominal examination, palpation of the lymph nodes, and colonoscopic examination of the interior colon and rectum) [4, 5] , and laboratory findings (blood in the stool, ACE, CA19-9) [6] . While its exact causes are still poorly understood, several modifiable (lifestyle, inflammatory diseases, microbiota imbalance) [7] [8] [9] , and non-modifiable factors contribute to CRC pathogenesis. The latter include ethic/ racial background, and polymorphic variants in inflammatory mediators, including cytokine [10] [11] [12] .
Interleukin (IL)17 is a 155 amino acids pro-inflammatory cytokine, and is produced by Th17 cells [13, 14] . IL-17 belongs to family of six homologous proteins, designated IL-17A through IL-17F [15, 16] , of which IL-17A and IL-17F are the most investigated. Several factors trigger the release of IL-17, including IL-6 and TGF-β, which stimulate the differentiation of CD4 + T cells into IL-17-producing Th17 cells [13, 14, 17] . Functionally, IL-17 induces the production of pro-inflammatory chemokines and cytokines, including IL-1, IL-6, TNF-α, G-CFS. These bind high-affinity receptors on epithelial cells, endothelial cells, fibroblasts and other immune cells, and trigger a local inflammatory response [13, 18] . IL-17 production is tightly regulated, and over-production of IL-17 induces a state of low-grade chronic inflammation [18] , associated with a myriad of pathologies, including allergies, celiac disease, and cancers, including colorectal cancer [15, [19] [20] [21] . Recently, it was suggested that elevated levels of IL-17A-producing cells are associated with poor prognosis of CRC, principally resulting from increased VEGFA expression [22] [23] [24] . IL-17A gene is located on chromosome 6 (6p12.2), and contains 3 exons and 2 introns spanning 4252 bp. Several polymorphic variants in IL-17A gene were reported, of which some were functional. A recent Tunisian study involving 102 CRC patients demonstrated positive association of rs2275913 minor (A) allele with increased susceptibility to CRC, and with CRC-associated features, such as tumor localization, tumor differentiation, and TNM stage [10] . A similar study on Chinese patients confirmed the positive association of rs2275913 with increased susceptibility to colorectal [19] and other cancers [15, 20, 24] . As other variants in IL-17A may be associated with CRC susceptibility, here we investigated the association of six polymorphic variants in IL-17A gene with the presence of CRC and accompanying features, in Tunisian population comprising of 294 patients with CRC, and 263 healthy cancer-free control subjects.
Subjects and Methods

Study subjects
This was a retrospective case-control study, performed at the outpatient oncology service of Saleh Azeiz Hospital (Tunis, Tunisia). Between February 2014 to October 2016, 294 subjects with CRC (mean age 58.8 ± 14.4 years), and 263 cancer-free control women (mean age 57.2 ± 18.1 years), comprising university and hospital employees, or volunteer women, were recruited into the study. None of control subjects reported personal or family history of CRC, and were matched to CRC cases according to self-declared ethnic origin. CRC assessment was based on clinical examination, colonoscopy, and histopathology on isolated biopsies; all cases had these tests done.
Demographic and clinical information were collected for CRC patients from clinical records, and by personal interview using a unified questionnaire by referring physician. These included gender, age at study entry and at CRC diagnosis, anemia, hypertension, and smoking history. Detailed histological assessment (differentiation status), tumor localization (rectum or colon/sigmoid), and treatment were recorded for all patients. The study was done according to Helsinki II declaration, and approved by the research & ethics committees of Saleh Azeiz Hospital and El Manar University in Tunis; all participants provided informed consent.
IL-17A genotyping
We identified six single nucleotide polymorphisms (SNP) in IL-17A gene with a minor allele frequency (MAF) ≥5%, which were reported in the literature with clinical relevance using NCBI Entrez Gene SNP Geneview. IL-17A genotyping was done by VIC-and FAM-labelled allelic discrimination method, using assay-on-demand TaqMan assays ordered from Applied Biosystems (Foster City, NJ). The reaction was performed in 6 μl volume on StepOne Plus real-time PCR system, according to manufacturer's instructions (Applied Biosystems). Replicate blinded quality control samples were included to check for the reproducibility of the genotyping results; concordance was > 99%. The average successful genotyping rate for each sample and SNP was 97.9%.
Statistical analysis
Statistical analysis was performed by SPSS version 23 (IBM; Armonk, NY). Continuous data were presented as mean ± SD, and categorical variables were listed as percent of total. Student's t-test, and Pearson χ 2 test was used for assessment of differences in means and inter-group significance, respectively. Power calculation was done by Genetic Power Calculator (http://pngu.mgh.harvard.edu/~purcell/cgibin/cc2k.cgi). The parameters used were 294 CRC patients and 263 control subjects, minor allele frequency (MAF) for the tested variants in CRC patients, estimated prevalence of CRC in Tunisia, along with genotypic relative risk for heterozygote (1/2) and minor allele homozygous (2/2). Assuming these parameters, the overall average power was calculated at 69.1%. Haploview 4.2 (www.broad.mit.edu/mpg/ haploview) was used in testing Hardy-Weinberg equilibrium (HWE). Frequencies for Caucasians (CEU), African Americans of the American Southwest (ASW) and Yoruban in Ibadan, Nigeria (YRI) were obtained from HapMap release #28, for comparison of allele frequencies obtained in this study to those previously reported. All analyses were performed under the assumption of additive genetic effect. Haploview 4.2 was used to check linkage disequilibrium (LD) between SNPs, and haplotype patterns. IL-17A haplotypes was reconstructed by the expectation maximization method. Of the possible 64 IL-17A haplotypes, 9 were found to be common (frequency > 1.5%), and were included in further analysis. Taking control group as reference, logistic regression analysis was used for determining odds ratios (OR) and 95% confidence intervals (95%CI) associated with CRC risk. Statistical significance set at P < 0.05.
Results
Study subjects
The demographics and clinical characteristics of study participants are shown in Table 1 . Mean age at entry of study, gender, body-mass index (BMI), and hypertension were comparable between CRC patients and control subjects. Significant differences between CRC cases and controls were noted in the number of smokers (P = 0.028), and incidence of anemia (P = 0.005). Accordingly, we selected these as the main covariates that we controlled for in subsequent analysis. Most CRC cases involved the colon and sigmoid (62%), and most were treated with chemotherapy (74.5%).
Association studies
The genotype distributions of the tested IL-17A variants were in HWE among study subjects ( Table 2 ). MAF of the tested IL-17A variants in CRC patients and control subjects are presented in Table 2 . Of the IL- Boldface indicates statistically significant differences. a Genotypes were coded as per "1″ = major allele, "2" = minor allele. b Number of subjects (frequency). Boldface indicates statistically significant differences. a Models controlled for gender, BMI, anemia, and smoking.
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17A SNPs analyzed, higher MAF of rs10484879 (P < 0.001) was seen in CRC cases than in control subjects. MAF of the remaining five tested variants were comparable between CRC patients and control subjects. Carriage of rs10484879 minor allele correlated with positive family history of CRC and other cancers (P = 0.002), CRC staging (P = 0.044), CRC treatment (P = 0.038), and with chemo body reaction (P = 0.001).
The distribution of IL-17A genotypes in CRC patients and control subjects are listed in Table 3 . Significant differences in the distribution of IL-17A rs10484879 (P < 0.001) genotypes were seen between CRC cases compared to control subjects. The association of IL-17A rs10484879 with CRC persisted after controlling for gender, BMI, anemia, and smoking (P = 0.003). The risk of CRC associated with a specific IL-17A genotype was further confirmed by testing the effect of gender, BMI, anemia, and smoking as confounders. Results from Table 4 confirmed the association of rs10484879 with CRC under the codominant (aP < 0.001), dominant (aP < 0.001), and log-additive (aP < 0.001) genetic models. In addition, rs3748067 was found to be associated with CRC under the codominant (P = 0.003) and dominant (P = 0.04) only. The association of both rs10484879 and rs3748067 with CRC was seen only in heterozygous carriers (Table 4) 
Haploview analysis
Varied LD was noted between the even tested IL-17A variants, and further analysis was limited to only 4-locus (rs3819024-rs2275913-rs10484879-rs7747909) (Fig. 1) . Among these, common haplotype (> 2% of total) seen in 7 of the possible 16 haplotypes. Haploview analysis identified the 4-locus IL-17A haplotypes AGTG (P < 0.011), and GATG (P = 0.036) to be positively associated with CRC (Table 5 ).
Discussion
Several studies highlighted the role of the immune system in gastrointestinal pathologies [25, 26] , including CRC [22, 23, 27] . In this regard, it was shown that a state of dysregulated anti-inflammatory and pro-inflammatory cytokine balance accompany the pathogenesis of CRC. Despite the central role of IL-17 in cancer pathogenesis [28] [29] [30] , including CRC [19, 22] , to our knowledge, few studies addressed the involvement of IL-17 in CRC in Tunisia, often with inconclusive findings. In this context, we analyzed the association between IL-17A rs3819024, rs2275913, rs3819025, rs10484879, rs7747909, and rs3748067 gene variants and the occurrence of CRC. Results obtained demonstrated positive association of IL-17A rs10484879 SNP and AGTG and GATG haplotypes with CRC. This is the first study that identifies the positive association of these haplotypes with increased risk of CRC.
Heightened IL-17 expression was documented for several tumors, including hepatocellular carcinoma [21] , cervical cancer [31] , lung cancer [32] , bladder cancer [20] , colorectal cancer [22] , and others [19] . According to these studies, IL-17 facilitates tumor progression by inducing angiogenesis. For example, increased intra-tumor accumulation of IL-17A-producing cells was associated with an increased vasculogenesis in hepatocellular carcinoma [33] , and increased intratumor Tc17 cell activity promoted vasculogenesis in cervical cancer [31] . Furthermore, elevated levels of IL-17A-producing cells was associated with increased lymphangiogenesis in lung cancer [34] .
There is growing evidence that IL-17 can promote CRC progression, via an incompletely understood mechanism. It was shown that increased abundance of IL-17A-producing cells, and heightened expression of IL-17 facilitate CRC progression of by inducing a state of enhanced angiogenesis [19, 22] . It was also suggested that CRC progression resulted from altered activity of Th17 cells, and/or imbalance of Th1/Th2 ratio [35] . This was highlighted by the findings that functional Th1 cells and Th17 cells clusters produce opposite effects on CRC patient survival, whereby strong Th17 expression was associated with poor cancer prognosis, when compared to strong Th1 profile, which was associated with prolonged and sustained CRC-free survival [23, 35] . In contrast, Th2 did not predict prognosis [23] .
Recruitment of CRC patients was based on clinico-pathological findings, which were obtained irrespective of family history, from clinical records of patients with colon and rectal cancer. On the other hand, control subjects were blood donors, or volunteers from the community, with no personal or CRC family history (CC or RC). Both modifiable (BMI, smoking) and non-modifiable (age, gender, ethnic background) factors contribute to CRC development. This was highlighted by the link of obesity with increased risk of CRC [1, 8, 9] , and by the association of weight gains during adulthood with heightened risk of colon cancer in men [8] . Accordingly, the contribution of key covariates to the association of IL-17A variants and haplotypes and overall CRC risk was addressed throughout the study.
In this retrospective case-control study, we investigated the association between CRC risk and the six IL-17A gene variants rs3819024, rs2275913, rs3819025, rs10484879, rs7747909, and rs3748067. IL-17A gene is located on chromosome 6, position 6p12.2, and contains Earlier studies reveal an association between IL-17A rs2275913 variant and cancers other than CRC, such as breast cancer [24] , gastric cancer [15, 16, 21, 36] , bladder cancer [20] , and cervical cancer [29, 31] . A recent meta-analysis of 26 case-control studies, comprising 20 studies on Asians and 6 studies on Caucasians, and involving 7872 cases, confirmed that IL-17A rs2275913 (and IL-17F rs763780) polymorphisms is associated with increased risk for some (gastric, cervical, CRC), but not all (hepatocellular carcinoma) cancer types [37] . It is noteworthy that the association of rs2275913 with CRC was seen only under dominant genetic model, and was more pronounced in Asians than Caucasians [37] . This highlights the need for additional studies on related and distant populations aimed at establishing a role for the IL-17A rs2275913 as a genetic marker of CRC, and possibly associated features.
In our hands, there was lack of association between rs2275913 and CRC. This was in apparent disagreement with recent Tunisian [10] , and Iranian [12] studies, which suggested an association between rs2275913 IL-17A gene variant and CRC. These apparent discrepancies are attributed to ethnic differences [12] , bias in diagnosing CRC, and the study design. Furthermore, unlike our study which included 293 CRC patients, both studies of Omrani on Tunisians (102 CRC patients and 139 controls), and Nemati on Southern Iranian (202 patients and 203 controls) were smaller in size, and with the magnitude of the association obtained, this question the relevancy of the conclusions reached.
In addition, haploview analysis demonstrated the association of haplotypes AGTG and GATG with CRC. These were constructed based on the LD pattern established, which necessitated removal of rs3819025, rs3804513, and rs3748067 from the block, owing to absence of LD with remaining variants. Whereas previous studies identified select haplotypes associated with breast cancer [24] , but not with CRC [12] . Difference between our results and those of Nemati are likely attributed to ethnic background (Iranian vs. Tunisian), sample size, and experimental interpretation [12] .
Conclusion
In conclusion, our study showed a positive association IL-17A rs104284879, as well as AGTG and GATG haplotypes with CRC. Our study has strengths. First, cases and controls were ethnically assimilated, thus reducing the problems of genetic background differences. Second, we used tag-SNPs, thus increasing the coverage of IL-17A gene. However, our study had also limitations, namely the relatively limited sample size (293 patients) which did not allow for subgroup analysis, and did not provide for addressing cause-effect relationship, given its retrospective case-control design. In addition, some possible sources of heterogeneity, including selection of controls, and proper assessment of the contribution of lifestyle/environmental factors, were not explored. Follow-up studies on additional IL-17A SNPs, and populations of different ethnic origins are needed to confirm, or alternatively rule of the association of IL-17A SNPs with altered risk of CRC.
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